On ECHEMI
Home > Drugs > Mesna Injection

Mesna Injection

Function and Efficacy

This product is a compound containing cysteine, which can combine with the toxic metabolites of repeatedly activated cyclophosphamide or ifosfamide to form non-toxic products that are quickly excreted from the body through urine, preventing urinary system damage such as hemorrhagic cystitis caused by the use of the above anticancer drugs. Because the excretion rate of this product is faster than that of cyclophosphamide, ifosfamide and their metabolites, it should be used repeatedly.

Ingredients

α-Mercaptoethylsulfonic acid sodium salt

Name Description Content CAS NO. Manufacturer
MesnaIngredients

This product is a compound containing cysteine, which can combine with the toxic metabolites of repeatedly activated cyclophosphamide or ifosfamide to form non-toxic products that are quickly excreted from the body through urine, preventing urinary system damage such as hemorrhagic cystitis caused by the use of the above anticancer drugs. Because the excretion rate of this product is faster than that of cyclophosphamide, ifosfamide and their metabolites, it should be used repeatedly.

More
19767-45-4 17

Appearance

This product is a colorless, clear liquid with a special odor similar to garlic.

Indication

This product can prevent urinary epithelial toxicity such as hemorrhagic cystitis caused by high-dose ifosfamide or cyclophosphamide for tumor chemotherapy. It works together with anti-tumor chemotherapy drugs ifosfamide or cyclophosphamide as a urinary system protector.

Usage and Dosage

The commonly used dose of this product is 20% of the dose of cyclophosphamide, ifosfamide, and clofosamide, intravenously or intravenously, and the administration time is 0 hours (the same time as the cytostatics), 4 hours later, and 8 hours later, for a total of 3 times. For children, the number of doses should be more frequent (for example, 6 times) and at shorter intervals (for example, 3 hours). When using cyclophosphamide for continuous intravenous drip, a large dose of this product is injected intravenously at 0 hours of treatment, and then this product is added to the cyclophosphamide infusion and administered simultaneously (the dose of this product can be as high as 100% of the dose of cyclophosphamide). Use this product continuously for about 6 to 12 hours after the infusion is used up (the dose can be as high as 50% of the dose of cyclophosphamide) to protect the urethra.

Adverse Reactions

Venous irritation and allergic reactions (such as skin and mucous membrane reactions) are rare. When a single dose of this product exceeds 60 mg/kg body weight, nausea, vomiting, cramping abdominal pain and diarrhea may occur.

Precautions

Not yet clear.

Drug Interactions

In test tube experiments, this product is incompatible with cisplatin and nitrogen mustard.

Storage

Keep in a dark place and sealed. 36 months

Packaging Specification

2 ml: 0.2 g

Manufacturer

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

  • Founded in:

    1997-04-28
  • Address:

    No. 38 Huanghe Road, Lianyungang Economic and Technological Development Zone
  • Tax NO.:

    9132070070404786XB
  • Registered Funds:

    6,379,002,274 yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.